Aparna Parikh, MD
Hematology & Oncology · Boston, MANPI 1154557650
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,627 of the $182,978 with a category attached, or 71.9%. It is spread thinly across 25 manufacturers, the largest accounting for just 13.3%. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $1143.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- Pfizer$22K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Incyte Corporation$17K
- Seagen Inc.$15K
- Regeneron$11K
- plus $75K from 19 others
Across 104 payments — averaging $45,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.9M
- GSK$1M
- Genentech, Inc.$643K
- E.r. Squibb & Sons, L.L.C.$439K
- Merck$195K
- Eli Lilly$157K
- plus $346K from 7 others
What the payments were for
- Consulting fees$131,62772%
- Speaking & faculty fees$16,5399%
- Travel & lodging$31,97417%
- Food & beverage$2,8382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 11 | $24,293 |
| Pfizer | 13 | $22,174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $18,730 |
| Incyte Corporation | 20 | $16,590 |
| Seagen Inc. | 17 | $15,165 |
| Regeneron | 15 | $10,917 |
| Mirati Therapeutics, Inc. | 7 | $9,825 |
| Array Biopharma Inc | 13 | $9,021 |
| E.r. Squibb & Sons, L.L.C. | 2 | $6,223 |
| Foundation Medicine, Inc. | 4 | $5,315 |
| Boehringer Ingelheim International GmbH | 2 | $4,977 |
| AstraZeneca | 3 | $4,452 |
| Sirtex Medical Inc | 3 | $4,209 |
| Eli Lilly | 10 | $4,073 |
| Exelixis Inc. | 7 | $4,063 |
| Lilly USA, LLC | 3 | $3,500 |
| AbbVie | 2 | $3,038 |
| Amgen | 1 | $2,744 |
| Merck | 5 | $2,648 |
| Janssen Research & Development, LLC | 2 | $2,555 |
| Exact Sciences | 4 | $2,173 |
| Delcath Systems | 1 | $1,800 |
| Taiho Oncology, Inc. | 1 | $1,650 |
| Bayer | 1 | $1,526 |
| F. Hoffmann-la Roche AG | 1 | $1,320 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$18,536
- BRAFTOVI$14,776
- TUKYSA$14,571
- KRAZATI$9,806
- FOUNDATIONONE CDX$5,315
- Enhertu$4,371
- SIR-Spheres Microspheres$4,147
- LIBTAYO$3,811
- JEMPERLI$3,200
- LUMAKRAS$2,744
- Cologuard Collection Kit$1,990
- The Cologuard Plus Collection Kit$1,990
- Hepzato Kit$1,800
- Lonsurf$1,650
- Stivarga$1,526
- Non-Covered Product$1,320
- FOUNDATIONONE LIQUID$125
- FOUNDATIONFOCUS$125
- FOUNDATIONONE HEME$125
- FOUNDATIONONE$125
How this compares
$182,978 in reported general payments places this provider in the 90th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.